KYTHERA’s double-chin treatment Kybella now available in USA

20 June 2015

US aesthetic medicine specialist KYTHERA Biopharmaceuticals (Nasdaq: KYTH) on Friday announced the US availability of Kybella (deoxycholic acid) injection, the first and only Food and Drug administration-approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition also known as “double chin.”

Kybella was approved in April by the FDA (The Pharma Letter April 30), and can now be purchased by physicians who have been trained on the safe use of the product and its approved indication.

Keith Leonard, chief executive of KYTHERA, which is the subject of an agreed $2.1 billion acquisition by Allergan (NYSE: AGN; TPL June 17), has previously suggested that Kybella will generate sales of at least $500 million in the USA, and eventually match that level in international revenue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK